UNSPSC 51383310: Amfenac sodium

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PPF9V8J28Y. European Medicines Agency schedules Amfenac sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00433MIG. Amfenac sodium generally arises in the molecular formula C15H12NO3.NA.H2O. The term 'amfenac sodium' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule amfenac sodium under HS 29225000 and SITC 51467.

As of Q4 2014, AMFENAC SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C(=O)C2CCCC(C2N)CC(=O)[O-].O.[NA+].

UNSPSC 51383310 Amfenac sodium is a Commodity code that nominally covers a specific nonsteroidal anti-inflammatory drug, but recent state and local procurement activity under this code does not reflect targeted purchases of amfenac itself. Instead, the opportunities tagged to it span pharmaceutical procurement broadly — including naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products. The mismatch between the code's nominal scope and actual buying patterns suggests the code may be applied inconsistently across state and local procurement systems, or that amfenac procurement activity has been absorbed into broader pharmaceutical supply contracts. State and local issuing bodies using this code include county health agencies (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota and Oregon).

Recent activity centers on Florida and the Upper Midwest. Seminole County issued an IFB (IFB60459723LAS, due July 26, 2023) for naloxone and safe drug deactivation systems with quarterly deliveries to its Community Health Building in Sanford. The Texas HHS Commission posted an exploratory RFI (HHS0017013, April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with awards effective July 1, 2026, and participation from Oregon. Vendors pursuing generic pharmaceutical supply and cooperative purchasing agreements should track the MMCAP cycle closely; the Texas RFI signals early-stage interest in alternative contracting models that may mature into formal solicitations.